Celltrion stock | 2026 trend & analyst price target

Celltrion

KOSE:A068270

₩ 199.700,00

₩-1.800,00 (-0,89%)

199.700,00 ₩

₩-1.800,00 (-0,89%)

End-of-day quote: 04/10/2026

Celltrion Stock Value

Analysts currently give Celltrion a rating of Outperform.

Outperform

Celltrion Company Info

EPS Growth 5Y

-1,80%

Market Cap

₩44.068,13 B

Long-Term Debt

₩86,60 B

Annual earnings

N/A

Dividend

₩738,89

Dividend Yield

0,37%

Founded

2002

Industry

Health Care

Country

South Korea

Website

Celltrion

ISIN Number

KR7068270008

Website

http://www.celltrion.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

₩260.000,00

30.2%

Last Update: 04/10/2026

Analysts: 24

Highest Price Target ₩290.000,00

Average Price Target ₩260.000,00

Lowest Price Target ₩170.000,00

In the last five quarters, Celltrion’s Price Target has risen from ₩221.026,03 to ₩246.952,38 - a 11,73% increase. Twenty Two analysts predict that Celltrion’s share price will increase in the coming year, reaching ₩260.000,00. This would represent an increase of 30,20%.

Top growth stocks in the health care sector (5Y.)

What does Celltrion do?

Celltrion, Inc., a biopharmaceutical company, focusing on developing, manufacturing, and commercializing proprietary biosimilars and innovative monoclonal antibodies. With a strong commitment to enhancing patient care through accessible medical treatments, the company utilizes advanced biotechnological processes, including bioengineering and mammalian cell-culture technology, to create products that are essential for various therapeutic needs. The company operates within a rapidly evolving globa...

The primary mission of the company revolves around the development of biopharmaceutical medicines, specifically targeting diseases such as cancer and immune disorders. This includes a range of therapeutic proteins designed to mimic and enhance the effectiveness of existing biological therapies. The company maintains a dual focus on both biopharmaceutical and chemical medicines, ensuring a diversified approach to its research and development efforts, which subsequently enriches its product pipeline and market offerings.

Business Segments

The company organizes its operations into three primary business segments: biopharmaceutical medicines, chemical medicines, and other products or services. Within the biopharmaceutical medicines segment, the company focuses on developing, manufacturing, and selling various therapeutic proteins, including monoclonal antibodies specifically intended for treating oncological conditions. Notable products include Remsima, Yuflyma, Herzuma, and Truxima, which are recognized for their efficacy in treating numerous immune-related and oncological diseases.

In the chemical medicines segment, the company pursues the development and commercialization of small-molecule drugs produced through synthetic processes. This segment encompasses a broad range of therapeutic areas, including cardiovascular diseases, diseases of the nervous system, and infectious diseases, reflecting the company’s intent to address diverse medical needs.

Business Strategy

The company adopts a multi-faceted business strategy to enhance its competitive edge and maintain sustainable growth. Central to its strategic direction is a commitment to innovation and the continuous improvement of its research and development endeavors. The company recognizes the delicate balance between innovating new products and ensuring regulatory compliance, particularly as it endeavors to introduce new therapeutic agents to the market. This implies a robust pipeline of products that undergo rigorous testing and validation processes.

Another critical pillar of the company’s business strategy is the pursuit of strategic partnerships and collaborations with other pharmaceutical entities and research institutions. This approach helps in leveraging complementary strengths and accessing additional resources, which can accelerate the development timeline for new drugs and ultimately lead to enhanced market position and profitability.

Investments in technology and infrastructure further bolster the company’s strategic positioning. By maintaining state-of-the-art production facilities and adopting the latest advancements in biotechnology, the company can ensure high-quality production standards that meet the increasing global demands for biopharmaceuticals.

Products and Services

The company’s portfolio encompasses a diverse array of products and services, reflecting its dual focus on biopharmaceutical and chemical medicines. In the realm of biopharmaceuticals, the company prides itself on its monoclonal antibody products, which are designed to target specific diseases effectively. These include treatments for immune disorders and various cancers, leveraging the advanced biomanufacturing capabilities of the company to ensure precision and efficacy in every batch produced.

In addition to monoclonal antibodies, the company also provides a selection of biosimilars that offer cost-effective alternatives to existing biologic therapies. This fulfills a critical market need and contributes to the overall goal of making healthcare more accessible.

On the chemical medicine side, the company produces a range of therapeutic agents aimed at cardiovascular disease management, HIV treatments, and conditions impacting the nervous system. By developing these chemical medications, the company serves to complement its biopharmaceutical offerings, ensuring a comprehensive approach to patient care.

Geographical Markets Served

The company serves a diverse set of geographical markets, predominantly focusing on domestic and Asian regions. With substantial sales figures indicating healthy market penetration, it continues to explore opportunities for international expansion.

Seasonality

Market dynamics such as product launches, regulatory approvals, and competitive actions can influence seasonal trends in revenue generation.

Customers

The company serves a diverse clientele, including healthcare providers such as hospitals, oncology centers, and pharmacies. It also engages in partnerships with governmental and non-governmental organizations focused on improving healthcare accessibility.

Sales and Marketing

In terms of marketing and distribution, the company adopts a multi-channel approach. This includes direct sales teams, distributor partnerships, and online platforms. The strategic focus is placed on educating healthcare professionals and patients regarding product benefits and proper usage, thus ensuring better patient outcomes and adherence.

History

Celltrion, Inc. was founded in 2002.

Celltrion Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Biopharmaceutical products:** 70% **Biosimilars:** 20% **Chemical pharmaceuticals:** 10% **TOP 3 markets:** **USA:** 40% **Europe:** 35% **Asia (excl. Korea):** 15% Celltrion, Inc. generates the majority of its revenue from biopharmaceutical products, especially through the develop...

At which locations are the company’s products manufactured?

**Production Sites:** - Incheon, South Korea - Cheongju, South Korea Celltrion, Inc. mainly produces its biopharmaceutical products in South Korea. The main production facilities are located in Incheon and Cheongju. These sites are equipped with state-of-the-art technology to support the manufactur...

What strategy does Celltrion pursue for future growth?

**Revenue growth:** 10.5% (2024) **R&D investments:** 15% of revenue (2024) Celltrion, Inc. pursues a growth strategy that is strongly focused on research and development (R&D). The company invests significantly in the development of new biosimilars and innovative biopharmaceutical prod...

Which raw materials are imported and from which countries?

**Main raw materials:** Biopharmaceutical active ingredients, cell cultures **Countries of origin:** USA, Germany, China Celltrion, Inc. is a leading biopharmaceutical company specializing in the development and production of biosimilars and biopharmaceutical products. The production of such produ...

How strong is the company’s competitive advantage?

**Market share in the biopharmaceutical industry:** Approx. 4% (2024, estimated) **R&D expenses:** 15% of revenue (2024, estimated) **Product pipeline:** Over 20 biosimilars and biopharmaceuticals in development (2025) Celltrion, Inc. has a significant competitive advantage in the biopharma...

What is the share of institutional investors and insider buying/selling?

**Institutional investor share:** Approx. 45% (estimated for 2025) **Insider purchases/sales:** No significant transactions in the last quarter (2025) The institutional investor share of Celltrion, Inc. is around 45%, indicating a strong interest from investment funds and other major financial inst...

What percentage market share does Celltrion have?

**Market share of Celltrion, Inc.:** Estimate 5-7% (2025) **Main competitors and their market shares:** 1. **Roche Holding AG:** 15-18% 2. **Amgen Inc.:** 12-15% 3. **Novartis AG:** 10-13% 4. **Pfizer Inc.:** 8-11% 5. **Johnson & Johnson:** 7-9% 6. **Celltrion, Inc.:** 5-7% 7. **Biogen Inc.:**...

Is Celltrion stock currently a good investment?

**Revenue growth:** 10% (2024) **Research and development ratio:** 15% of revenue (2024) **Market share in the biosimilars segment:** 20% (2024) Celltrion, Inc. recorded a revenue growth of 10% in 2024, attributed to strong demand for biosimilars and successful market expansion. The company has est...

Does Celltrion pay a dividend – and how reliable is the payout?

**Dividend yield:** 1.5% (2025, estimated) **Dividend history:** No regular payouts in recent years Celltrion, Inc. has not paid regular dividends in the past. Instead, the company has focused on reinvesting its profits in research and development as well as expanding its production capacities. Th...

New support ticket

Explore

Celltrion Stock Value

Celltrion Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Celltrion do?

Celltrion Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Celltrion Stock Value

Celltrion Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Celltrion do?

Celltrion Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.